Skip to main content
Clinical Trials/NCT02011815
NCT02011815
Completed
Not Applicable

A Prospective Study of Exploring Possible Biological Linkage Between Circadian Disruption and Cancer Progression

Seoul National University Hospital1 site in 1 country236 target enrollmentNovember 10, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Neoplasms
Sponsor
Seoul National University Hospital
Enrollment
236
Locations
1
Primary Endpoint
Progression-free survival
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this study is to explore the possible association between the circadian disruption and cancer progression.

Detailed Description

The biological markers that are assumed to bridge this association are measured and analyzed.

Registry
clinicaltrials.gov
Start Date
November 10, 2013
End Date
June 15, 2019
Last Updated
6 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age: 18-70
  • Breast cancer patients who are getting chemotherapy for the first time in life
  • Patients are either having stage 4 cancer or starting neoadjuvant chemotherapy.
  • Patient have signed on the informed consent, and well understood the objective and procedure of this study

Exclusion Criteria

  • Patients already have received chemotherapy
  • Patient had another cancer (except thyroid cancer) within 5 years
  • Patient with severe medical condition
  • Patient had taken psychiatric medication more than 1 month in life
  • Patient worked the night shift for more than 1 month in 6 months

Outcomes

Primary Outcomes

Progression-free survival

Time Frame: 3 years (and more) after recruitment

The data progression-free survival will be done by reviewing patients' medical record.

Secondary Outcomes

  • Objective sleep cycle measures(Baseline, after 1 month, after 6 month, after 12 month)
  • Sleep quality measures(Baseline, after 1 month, after 6 month, after 12 month)
  • Distress related measure(Baseline, after 1 month, after 6 month, after 12 month)
  • Posttraumatic Stress-related symptom measure(Baseline, after 1 month, after 6 month, after 12 month)
  • Genetic polymorphism(Baseline)
  • Physiological measures(Baseline, after 1 month, after 6 month, after 12 month)
  • Cortisol level(Baseline)
  • Inflammatory markers(Baseline)
  • Overall survival(3 years (and more) after recruitment)
  • Quality of Life measure(Baseline, after 1 month, after 6 month, after 12 month)
  • Cancer related Fatigue(Baseline, after 1 month, after 6 month, after 12 month)
  • Menopausal symptom measure(Baseline, after 1 month, after 6 month, after 12 month)
  • Epigenetic Change(Baseline)
  • Circadian disruption(Baseline, after 1 month, after 6 month, after 12 month)
  • Personality measure(Baseline)
  • Melatonin(Baseline)

Study Sites (1)

Loading locations...

Similar Trials